1)Mercadante S and Arcuri E:Breakthrough pain in cancer patients:pathophysiology and treatment. Cancer Treat Rev 24:425-432, 1998
2)Payne R and Gonzales GR:Pathophysiology of pain in cancer and other terminal diseases. In:Oxford Textbook of Palliative Medicine, 3rd edition. edited by Doyle D, Hanks G, Cherney N, et al. Oxford University Press, Oxford, pp288-298, 2004
3)Mantyh PW, Clohisy, DR, Koltzenburg M, et al:Molecular mechanisms of cancer pain. Nature Rev Cancer 2:201-209, 2002
4)冨安志郎:がんの痛みのメカニズム.薬局 58:5-7,2007
5)的場元弘,吉本鉄介,余宮きのみ,他:WHO方式がん疼痛治療ガイドライン推奨量によるアセトアミノフェン:日本における有効性と安全性の多施設処方調査.ペインクリニック 28:1131-1139,2007
6)Dickenson AH:Mechanisms of analgesic actions of opiates and opioids. Br Med Bull 47:690-702, 1991
7)Mercadante S, Fulfaro F and Casuccio A:A randomized controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy:effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 38:1358-1363, 2002
8)Inturrisi CE:Narcotic analgesics in the management of pain. In:Analgesics:Neurochemical, Behavioral and Clinical Perspectives. edited by Kuhar M and Pasternak G. Raven Press, New York, p257, 1984
9)平山武司,矢後和夫:モルヒネの体内動態.医薬ジャーナル 37:75,2001
10)Southam MA:Transdermal fentanyl therapy:system design, pharmacokinetics and efficacy. Anti-Cancer Drugs 6:29, 1995
11)Donner B and Zenz M:Transdermal fentanyl:a new step on the therapeutic ladder. Anti-Cancer Drugs 6(Suppl 3):39, 1995
12)Davis MP, Varga J, Dickarson D, et al:Normal-release and controlled-release oxycodone:pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84, 2003
13)冨安志郎,的場元弘,龍 恵美,他:内服モルヒネレスキュードーズ簡略化の妥当性:5mg単位での鎮痛効果と副作用の多施設調査.ペインクリニック 29:S499-S506,2008
14)Colleau SM:The significance of breakthrough pain in cancer. Cancer Pain Release 12:1-9, 1999
15)日本医師会(編):がん緩和ケアガイドブック2008年版.青海社,東京,p4,2008